Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicenter, Open-label, Randomized, Phase 3 Trial

NCT05607329 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.

NCT NCT05607329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicenter, Open-label, Randomized, Phase 3 Trial
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Phase
Not applicable
Overall status
Recruiting
Start date
May 1, 2021
Completion date
May 1, 2028
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed ovarian cancer